Monoclonal Antibodies in the Treatment of Rheumatoid Arthritis

Abstract

Get full access to this article

View all access options for this article.

References

Goldberg

Morel

Chatenoud

Boitard

Menkes

Bertoye

. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmunity 1991; 4: 617–30.

Wendling

Wijdenes

Racadot

Morel-Fourrier

. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 1991; 18: 325–7.

Racadot

Wijdenes

Wendling

. Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5). Clin Exp Rheumatol 1992; 10: 365–74.

Horneff

Burmester

Emmrich

Kalden

. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991; 34: 129–40.

Reiter

Kakavand

Rieber

Schattenkirchner

Riethmüller

Krüger

. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991; 34: 525–36.

Moreland

Bucy

Tilden

Pratt

LoBuglio

Khazaeli

. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36: 307–18.

Moreland

Pratt

Mayes

Postlethwaite

Weisman

Schnitzer

. Minimal efficacy of a depleting chimeric anti-CD4 (cM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX) (abstract). Arthritis Rheum 1993; 36 (suppl):S39.

Choy

EHS

Pitzalis

Bijl

Kingsley

Panayi

. The amount of anti-CD4 monoclonal antibody (mAb) entering the rheumatoid (RA) joint may determine clinical efficacy (abstract). Arthritis Rheum 1993; 36 (suppl):S39.

Kirkham

Thien

Pelton

Pitzalis

Amlot

Denman

. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992; 19: 1348–52.

10.

Kirkham

Pitzalis

Kingsley

Chikanza

Sabharwal

Barbatis

. Monoclonal antibody treatment in rheumatoid arthritis: The clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991; 30: 459–63.

11.

Kyle

Coughlan

Tighe

Waldmann

Hazleman

. Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 428–9.

12.

Strand

Lipsky

Cannon

Calabrese

Wiesenhutter

Cohen

. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: Results of two phase II studies. Arthritis Rheum 1993; 36: 620–30.

13.

Isaacs

Watts

Hazleman

Hale

Keogan

Cobbold

. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748–52.

14.

Isaacs

Manna

Hazleman

Schnitzer

St. Clair

Matteson

. CAMPATH-1H in RA—a study of multiple IV dosing (abstract). Arthritis Rheum 1993; 36 (suppl):S40.

15.

Weinblatt

Coblyn

Maier

Anderson

Helfgott

Thurmond

. Sustained lymphocyte suppression after single dose CAMPATH™-1H infusion: An 8-month follow-up (abstract). Arthritis Rheum 1993; 36 (suppl):S40.

16.

Kavanaugh

Nichols

Lipsky

. Treatment of refractory rheumatoid arthritis with an anti-CD54 (intercellular adhesion molecule-1, ICAM-1) monoclonal antibody (abstract). Arthritis Rheum 1992; 35 (suppl):S43.

17.

Kavanaugh

Nichols

Davis

Rothlein

Lipsky

. Anti-CD54 (intercellular adhesion molecule-1; ICAM-1) monoclonal antibody therapy in refractory rheumatoid arthritis (abstract). Arthritis Rheum 1993; 36 (suppl):S40.

18.

Elliott

Maini

Feldmann

Long-Fox

Charles

Katsikis

. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681–90.

19.

Wendling

Racadot

Wijdenes

. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259–62.

20.

Tami

Parr

Brown

Thompson

. Monoclonal antibody technology. Am J Hosp Pharm 1986; 43: 2816–25.

21.

Gorman

Clark

. Humanisation of monoclonal antibodies for therapy. Semin Immunol 1990; 2: 457–66.

22.

Horneff

Sack

Kalden

Emmrich

Burmester

. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 1993; 91: 207–13.

23.

Horneff

Emmrich

Reiter

Kalden

Burmester

. Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy. J Rheumatol 1992; 19: 1845–50.